The details are as follows:
Interleukin-18 engineered for resistance to IL-18 binding protein (IL-18BP) and half-life extension to enhance its therapeutic potential
Session: Immune Modulation with Cytokines
Date and Time:
Location: Poster Section 4, Poster 20
Abstract #: 4076
Speaker/Lead Author:
Generation of tumor targeted self-assembling split IL-12 subunits for the treatment of cancer
Session: Immune Modulation with Cytokines
Date and Time:
Location: Poster Section 4, Poster 10
Abstract #: 4066
Speaker/Lead Author:
All posters will be made available at https://www.muraloncology.com/publications/ following the presentations.
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential and reach of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in
Contacts
Investors:
david.borah@muraloncology.com
Media:
katie.sullivan@muraloncology.com
![](https://ml.globenewswire.com/media/ZWE3MDYyYjUtNjY1YS00ZmI2LTkyNjAtODI4MDIxOWUyYTFmLTEyNzM4OTM=/tiny/Mural-Oncology-Inc-.png)
2024 GlobeNewswire, Inc., source